Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.5.1.4 (
deaminase
)
5,113
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Diphthamide is a highly modified histidine residue in eukaryal translation
elongation factor 2
(eEF2) that is the target for irreversible ADP ribosylation by diphtheria toxin (DT). In Saccharomyces cerevisiae, the initial steps of diphthamide biosynthesis are well characterized and require the DPH1-DPH5 genes. However, the last pathway step-amidation of the intermediate diphthine to diphthamide-is ill-defined. Here we mine the genetic interaction landscapes of DPH1-DPH5 to identify a candidate gene for the elusive
amidase
(YLR143w/DPH6) and confirm involvement of a second gene (YBR246w/DPH7) in the amidation step. Like dph1-dph5, dph6 and dph7 mutants maintain eEF2 forms that evade inhibition by DT and sordarin, a diphthamide-dependent antifungal. Moreover, mass spectrometry shows that dph6 and dph7 mutants specifically accumulate diphthine-modified eEF2, demonstrating failure to complete the final amidation step. Consistent with an expected requirement for ATP in diphthine amidation, Dph6 contains an essential adenine nucleotide hydrolase domain and binds to eEF2. Dph6 is therefore a candidate for the elusive
amidase
, while Dph7 apparently couples diphthine synthase (Dph5) to diphthine amidation. The latter conclusion is based on our observation that dph7 mutants show drastically upregulated interaction between Dph5 and eEF2, indicating that their association is kept in check by Dph7. Physiologically, completion of diphthamide synthesis is required for optimal translational accuracy and cell growth, as indicated by shared traits among the dph mutants including increased ribosomal -1 frameshifting and altered responses to translation inhibitors. Through identification of Dph6 and Dph7 as components required for the amidation step of the diphthamide pathway, our work paves the way for a detailed mechanistic understanding of diphthamide formation.
...
PMID:The amidation step of diphthamide biosynthesis in yeast requires DPH6, a gene identified through mining the DPH1-DPH5 interaction network. 2835 44
Diphthamide is a highly conserved modification of archaeal and eukaryal translation
elongation factor 2
(
EF2
) and yet why cells need
EF2
to contain diphthamide is unclear. In yeast, the first steps of diphthamide synthesis and the genes (
DPH1-DPH5
) required to form the intermediate diphthine are well-documented. However, the last step, amidation of diphthine to diphthamide, had largely been ill-defined. Remarkably, through mining genome-wide synthetic gene array (SGA) and chemical genomics databases, recent studies by Uthman
et al.
[PLoS Genetics (2013) 9, e1003334] and Su
et al.
[Proc. Natl. Acad. Sci. USA (2012) 109, 19983-19987] have identified two more diphthamide players,
DPH6
and
DPH7
. Consistent with roles in the amidation step,
dph6
and
dph7
deletion strains fail to complete diphthamide synthesis and accumulate diphthine-modified
EF2
. In contrast to Dph6, the catalytically relevant
amidase
, Dph7 appears to be regulatory. As shown by Uthman
et al.
, it promotes dissociation of diphthine synthase (Dph5) from
EF2
, allowing diphthine amidation by Dph6 to occur and thereby coupling diphthine synthesis to the terminal step in the pathway. Remarkably, the study by Uthman
et al
. suggests that Dph5 has a novel role as an
EF2
inhibitor that affects cell growth when diphthamide synthesis is blocked or incomplete and, importantly, shows that diphthamide promotes the accuracy of
EF2
performance during translation.
...
PMID:Decoding the biosynthesis and function of diphthamide, an enigmatic modification of translation elongation factor 2 (EF2) 2346 60